Skip to main content
Premium Trial:

Request an Annual Quote

SQI, Algorithme Building Assay for Heparin Immunogenicity Testing

NEW YORK (GenomeWeb News) – SQI Diagnostics and Algorithme Pharma today said they are co-developing a proof-of-concept assay for immunogenicity testing of heparin and heparin-based low molecular weight biosimilar compounds.

The assay is based on SQI's Ig Plex multiplexing technology and is expected to be available on all of the Toronto-based firm's fully automated analytical systems, including its SQIDlite and SQIDworks platforms.

The test will provide drug developers and contract research organizations quantitative results for all three isotopes of heparin-induced thrombocytopenia (HIT) antibodies in a single test, SQI and Algorithme said. Using SQI's automated platform will also improve the benefits of multiplexing and reduce the time and labor necessary to process and analyze blood samples during the drug development and immunogenicity testing, they added.

"Because HIT antibodies are potentially produced with all heparin-based biosimilars, Algorithme, with this proof of concept completed, will have a 'shelf-ready' multiplexed assay ready to implement and deliver very competitive HIT testing to the many pharmaceutical companies who are building heparin biosimilar compounds," Robert Masse, vice president of Large Molecule Bioanalysis of Aligorithme Pharma, said in a statement.

Based in Laval, Quebec, Algorithme provides early stage clinical development studies to pharmaceutical and biotechnology companies.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.